Starpharma Reports Positive Results From SARS-CoV-2 Antiviral Testing Of SPL7013

(RTTNews) - Starpharma announced that its VivaGel active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19. The SARS-CoV-2 antiviral testing of SPL7013 was conducted under contract by Melbourne-based 360Biolabs.

Starpharma said it is evaluating product concepts and formulation options for SPL7013, which may have potential applications in the prevention and management of COVID-19.

Jackie Fairley, Starpharma CEO, said: "We are now exploring a number of product opportunities, including a potential preventative application to reduce the risk of infection. Such a product could provide additional personal protection including for those in the frontline of this crisis, such as doctors, nurses and other essential workers."

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More